Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.
Riccardo Moia, Mohammad Almasri, Maria Elena Carazzolo et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II clinical trial analyzed the molecular landscape of 132 older patients with mantle cell lymphoma (MCL) from the FIL V-RBAC trial. Key findings revealed that ATM mutations were present in 41.7% of patients, and specific molecular lesions, including single-hit ATM alterations, were independently associated with progression-free survival. A 4-factor prognostic model was developed to stratify patient outcomes.
Key findings
- ATM mutations were found in 41.7% of patients, making it the most frequently mutated gene.
- Single-hit ATM alterations were linked to durable long-term remission in patients without additional risk factors.
- CD36 mutations were associated with adverse survival outcomes.
- A 4-factor molecular prognostic model identified distinct patient subgroups with significantly different outcomes.
Why it matters
Understanding the molecular determinants of outcomes in mantle cell lymphoma can enhance risk stratification and inform treatment decisions. This study highlights the potential for personalized approaches in managing MCL based on genetic profiling.